A recent Phase 3 clinical trial has been published concluding that treatment with selpercatinib resulted in superior progression-free survival and treatment-free survival compared to other therapies such as cabozantinib or vandetanib in patients with RET-mutant medullary thyroid cancer 155. This evidence concerns the gene RET and medullary thyroid gland carcinoma.